MESA LABORATORIES INC (MLAB)
Sector: Health Care
2026 Annual Meeting Analysis
MESA LABORATORIES INC · Meeting: September 8, 2026
Directors FOR
7
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of seven director nominees for a term of one year
Sullivan has served since 2009 and the stock's 3-year price return of -16.3% (negative absolute TSR) would require underperformance of the peer group median by 20+ percentage points to trigger a No vote; without confirmed peer-group TSR data showing that threshold is breached, the default FOR applies, and his long tenure as former CEO provides relevant strategic experience.
Kadia was appointed to the board in April 2026, well within the 24-month new-director exemption window, so the TSR underperformance trigger does not apply; he serves as CEO with relevant life sciences leadership experience.
Ladiwala joined in 2021 (approximately 5 years tenure), the stock's absolute 3-year TSR is negative (-16.3%), triggering a 20pp peer-underperformance threshold; however, without confirmed data showing the company underperforms its compensation peer group median by 20+ percentage points, the default FOR applies, and he serves as Lead Independent Director with no overboarding or attendance issues.
Alltoft joined in 2019 and the same TSR analysis applies as to other tenured directors; no overboarding, attendance issues, independence concerns, or familial relationships are disclosed.
Capone joined in 2024, which is within the 24-month new-director exemption window, so the TSR trigger does not apply; he chairs the Compensation Committee and brings relevant industry experience.
Hall joined in 2020 and the same TSR analysis applies as to other tenured directors; no overboarding, attendance issues, or independence concerns are disclosed.
Tripeny joined in 2022 and chairs the Audit Committee; the board designates him as an audit committee financial expert (former CFO-equivalent experience), all meetings were attended, and no independence or overboarding concerns are disclosed.
All seven director nominees receive a FOR vote determination. The stock's 3-year price return is negative (-16.3%), which sets a 20-percentage-point peer-underperformance threshold for a No vote under policy; however, confirmed peer-group TSR comparison data is not available in the filing to establish that the threshold is breached. Two directors (Kadia and Capone) joined within the past 24 months and are exempt from the TSR trigger entirely. No overboarding, attendance failures, independence violations, or familial relationships with management are disclosed for any nominee. The board discloses a skills matrix and Tripeny qualifies as audit committee financial expert.
Say on Pay
✓ FORCEO
Gary Owens
Total Comp
$6,599,891
Prior Support
94.2%%
The prior year say-on-pay vote received 94.2% support, well above the 70% threshold that would require a response, and the company has continued to engage proactively with shareholders. The pay program is heavily performance-based: approximately 87% of CEO target compensation is at-risk variable pay (well above the 50-60% policy minimum), with long-term equity awards split equally between performance stock awards tied to a 3-year relative total shareholder return metric versus the S&P Composite 1500 Healthcare Index, and time-based restricted stock units vesting over three years. The company maintains a meaningful clawback policy adopted in October 2023, no tax gross-ups, no guaranteed bonuses, and no excessive perquisites, and the compensation structure reflects genuine pay-for-performance alignment with no red flags under policy thresholds.
Auditor Ratification
✓ FORAuditor
Baker Tilly US, LLP
Tenure
2 yrs
Audit Fees
$1,526,181
Non-Audit Fees
$0
Baker Tilly has served as auditor since the second quarter of fiscal year 2025 (approximately 2 years of tenure), well below the 25-year threshold that would raise independence concerns. All fees paid in fiscal year 2026 were pure audit fees with zero non-audit, audit-related, tax, or other fees, so the non-audit fee ratio is 0% — far below the 50% trigger. No material restatements attributable to audit failure are disclosed, and Baker Tilly is a large national firm appropriate for a company of Mesa's size and complexity.
Overall Assessment
Mesa Laboratories' 2026 annual meeting presents three standard proposals — director elections, auditor ratification, and say-on-pay — all of which receive FOR vote determinations under our policy. The compensation program is strongly performance-oriented with 87% of CEO pay at risk, the auditor is newly engaged with zero non-audit fees, and no director triggers the overboarding, attendance, independence, or TSR underperformance thresholds sufficient to warrant a No vote.